We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kimberly-Clark (KMB) Q2 Earnings & Sales Top Estimates
Read MoreHide Full Article
Kimberly-Clark Corporation (KMB - Free Report) reported second-quarter 2020 results, with the top and the bottom line surpassing the Zacks Consensus Estimate. Also, earnings increased year over year. The top line improved slightly from the year-ago quarter’s level. The quarterly performance reflected sales growth in the Consumer Tissue segment amid the coronavirus outbreak. Also, savings from restructuring plans contributed to the results.
Quarter in Detail
Adjusted earnings came in at $2.20 per share, which surpassed the Zacks Consensus Estimate of $1.82 and increased 32% from the year-ago quarter’s figure.
Kimberly-Clark’s sales came in at $4,612 million, which surpassed the Zacks Consensus Estimate of $4,513 million. The top line increased from $4,594 reported in the year-ago quarter. Unfavorable currency movements put pressure on sales by 4%. Organic sales rose 4% year over year. Volumes rose 2% year over year. Also, net selling prices and product mix inched up 1% each.
In North America, organic sales in consumer products increased 12% but were down 3% in K-C Professional segment. Internationally, organic sales increased 3% across developed markets but fell 3% in developing and emerging markets.
Adjusted operating profit came in at $1,012 million, up from $789 million in the year-ago quarter. Results gained from higher organic sales and cost savings of $120 million and $55 million from the FORCE (Focused On Reducing Costs Everywhere) program and the 2018 Global Restructuring Program, respectively. Further, lower input costs stemming from decline in pulp costs benefited results. However, unfavorable currency translations, increased advertising expenses and a rise in selling, general and administrative costs negatively impacted adjusted operating profit.
KimberlyClark Corporation Price, Consensus and EPS Surprise
Personal Care Products: Sales of $2,229 million declined 2% year over year. Both net selling prices and volumes improved slightly while product mix rose up 2% year over year. Also, unfavorable currency rates hurt sales by 5%. Further, sales increased 4% in North America but decreased 9% in developing and emerging markets. The metric fell 8% across developed markets outside North America.
Consumer Tissue: Segment sales of $1,645 million rose 12% year over year. Net selling prices were up 1% while volumes increased 14% owing to higher demand amid coronavirus pandemic. However, product mix dropped 1%. Also, adverse currency movements hurt sales by 3%. Sales rose 22% in North America but decreased 9% in developing and emerging markets. The metric increased 8% in developed markets outside North America.
K-C Professional (KCP): Segment sales decreased 12% to $724 million. Volumes were down 16% owing to coronavirus-led woes. Net selling prices were up 4% and product mix increased 3%. Also, currency woes hurt sales by 2%. Sales fell 3% in North America and 35% in developing and emerging markets. The metric declined 12% in developed markets outside North America.
Other Financial Updates
The company ended the quarter with cash and cash equivalents of $1,448 million, long-term debt of $7,223 million and stockholders’ equity of $495 million.
Further, Kimberly-Clark generated cash from operating activities of $1,579 million during the quarter under review. Management incurred capital expenditures of $284 million.
Kimberly-Clark repurchased 0.3 million shares for $39 million in the quarter. Following this the company had temporarily suspended its share repurchase program effective Apr 24 amid the coronavirus outbreak. Nevertheless, management expects to restart the program from Jul 24.
2020 Outlook
Management forecasts 2020 net sales to grow 1-2% year over year. Further, Kimberly-Clark projects organic sales improvement of 4-5%. However, currency headwinds are likely to impact net sales by 3%, while business exits related to the 2018 Global Restructuring Program are also expected to slightly affect sales.
Management anticipates adjusted operating profit growth of 6-9% for the year. The company is on track with the 2018 Global Restructuring Program, which is aimed at lowering the company’s structural costs and improving financial flexibility. In 2020, management expects to generate total cost savings of $510-$560 million. This includes expected savings of $390-$420 million from the FORCE program and $120-$140 million from the 2018 Global Restructuring Program. Moreover, the company expects cost of key inputs to drop in the range of $150-$250 million. However, other manufacturing costs as well as advertising expenses are anticipated to rise in 2020. The company also expects interest expenses to fall in 2020.
Considering all factors, management envisions 2020 adjusted earnings per share of $7.40-$7.60, which indicates an increase from $6.89 reported in 2019.
Price Performance
Notably, this Zacks Rank #3 (Hold) stock gained 6.5% year to date against the industry’s decline of 5.1%.
The Clorox Company (CLX - Free Report) , with a Zacks Rank #2, has a long-term earnings growth rate of 5.9%.
The Kraft Heinz Company (KHC - Free Report) has a long-term earnings growth rate of 6% and a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Kimberly-Clark (KMB) Q2 Earnings & Sales Top Estimates
Kimberly-Clark Corporation (KMB - Free Report) reported second-quarter 2020 results, with the top and the bottom line surpassing the Zacks Consensus Estimate. Also, earnings increased year over year. The top line improved slightly from the year-ago quarter’s level. The quarterly performance reflected sales growth in the Consumer Tissue segment amid the coronavirus outbreak. Also, savings from restructuring plans contributed to the results.
Quarter in Detail
Adjusted earnings came in at $2.20 per share, which surpassed the Zacks Consensus Estimate of $1.82 and increased 32% from the year-ago quarter’s figure.
Kimberly-Clark’s sales came in at $4,612 million, which surpassed the Zacks Consensus Estimate of $4,513 million. The top line increased from $4,594 reported in the year-ago quarter. Unfavorable currency movements put pressure on sales by 4%. Organic sales rose 4% year over year. Volumes rose 2% year over year. Also, net selling prices and product mix inched up 1% each.
In North America, organic sales in consumer products increased 12% but were down 3% in K-C Professional segment. Internationally, organic sales increased 3% across developed markets but fell 3% in developing and emerging markets.
Adjusted operating profit came in at $1,012 million, up from $789 million in the year-ago quarter. Results gained from higher organic sales and cost savings of $120 million and $55 million from the FORCE (Focused On Reducing Costs Everywhere) program and the 2018 Global Restructuring Program, respectively. Further, lower input costs stemming from decline in pulp costs benefited results. However, unfavorable currency translations, increased advertising expenses and a rise in selling, general and administrative costs negatively impacted adjusted operating profit.
KimberlyClark Corporation Price, Consensus and EPS Surprise
KimberlyClark Corporation price-consensus-eps-surprise-chart | KimberlyClark Corporation Quote
Segment Details
Personal Care Products: Sales of $2,229 million declined 2% year over year. Both net selling prices and volumes improved slightly while product mix rose up 2% year over year. Also, unfavorable currency rates hurt sales by 5%. Further, sales increased 4% in North America but decreased 9% in developing and emerging markets. The metric fell 8% across developed markets outside North America.
Consumer Tissue: Segment sales of $1,645 million rose 12% year over year. Net selling prices were up 1% while volumes increased 14% owing to higher demand amid coronavirus pandemic. However, product mix dropped 1%. Also, adverse currency movements hurt sales by 3%. Sales rose 22% in North America but decreased 9% in developing and emerging markets. The metric increased 8% in developed markets outside North America.
K-C Professional (KCP): Segment sales decreased 12% to $724 million. Volumes were down 16% owing to coronavirus-led woes. Net selling prices were up 4% and product mix increased 3%. Also, currency woes hurt sales by 2%. Sales fell 3% in North America and 35% in developing and emerging markets. The metric declined 12% in developed markets outside North America.
Other Financial Updates
The company ended the quarter with cash and cash equivalents of $1,448 million, long-term debt of $7,223 million and stockholders’ equity of $495 million.
Further, Kimberly-Clark generated cash from operating activities of $1,579 million during the quarter under review. Management incurred capital expenditures of $284 million.
Kimberly-Clark repurchased 0.3 million shares for $39 million in the quarter. Following this the company had temporarily suspended its share repurchase program effective Apr 24 amid the coronavirus outbreak. Nevertheless, management expects to restart the program from Jul 24.
2020 Outlook
Management forecasts 2020 net sales to grow 1-2% year over year. Further, Kimberly-Clark projects organic sales improvement of 4-5%. However, currency headwinds are likely to impact net sales by 3%, while business exits related to the 2018 Global Restructuring Program are also expected to slightly affect sales.
Management anticipates adjusted operating profit growth of 6-9% for the year. The company is on track with the 2018 Global Restructuring Program, which is aimed at lowering the company’s structural costs and improving financial flexibility. In 2020, management expects to generate total cost savings of $510-$560 million. This includes expected savings of $390-$420 million from the FORCE program and $120-$140 million from the 2018 Global Restructuring Program. Moreover, the company expects cost of key inputs to drop in the range of $150-$250 million. However, other manufacturing costs as well as advertising expenses are anticipated to rise in 2020. The company also expects interest expenses to fall in 2020.
Considering all factors, management envisions 2020 adjusted earnings per share of $7.40-$7.60, which indicates an increase from $6.89 reported in 2019.
Price Performance
Notably, this Zacks Rank #3 (Hold) stock gained 6.5% year to date against the industry’s decline of 5.1%.
3 Consumer Staples Stocks Worth a Look
Procter Gamble Company (PG - Free Report) has a long-term earnings growth rate of 7.2% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Clorox Company (CLX - Free Report) , with a Zacks Rank #2, has a long-term earnings growth rate of 5.9%.
The Kraft Heinz Company (KHC - Free Report) has a long-term earnings growth rate of 6% and a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>